Gatifloxacin is an 8-methoxyfluoroquinolone with in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The antibacterial action of Gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Gatifloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections.
Gatifloxacin inhibits the activity of bacterial enzymes (DNA gyrase and a topoisomerase) that are necessary for proper DNA formation and replication. This fights infection by preventing bacteria from reproducing. Gatifloxacin is an antibiotic in the class of drugs called fluoroquinolones. It fights bacteria in the body. Gatifloxacin is used to treat bacterial infections of the lungs, sinuses, skin, and urinary tract and certain sexually transmitted diseases. Gatifloxacin may also be used for purposes other than those listed in this medication guide.
Gatifloxacin is an antibiotic used to treat various bacterial infections like sinusitis, bronchitis, and pneumonia. It is also used to treat urinary tract infections, kidney infections, and uncomplicated gonorrhea. Antibiotics will not work for colds, flu, or other types of viral infections.
Gatifloxacin pharmacokinetics are linear and time-independent at doses ranging from 200 to 800 mg administered over a period of up to 14 days. Steady-state concentrations are achieved by the third daily oral or intravenous dose of gatifloxacin. The mean steady-state peak and trough plasma concentrations attained following a dosing regimen of 400 mg once daily are approximately 4.2 g/mL and 0.4 g/mL, respectively, for oral administration and 4.6 g/mL and 0.4 g/mL, respectively, for intravenous administration.
CAS Number 160738-57-8